Revenue
2020
2021
2022
Cullinan Therapeutics, Inc. (CGEM)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $18.9M | $0 |
| Research & development | $187.4M | $142.9M | $148.2M | $91.9M | $57.8M | $43.2M |
| Operating expenses | $241.6M | $196.9M | $190.6M | $132.1M | $86.9M | $60.3M |
| Operating income | −$241.6M | −$196.9M | −$191.1M | $144.6M | −$68.0M | −$60.3M |
| EBITDAderived | −$241.3M | −$196.6M | −$190.8M | $144.7M | −$67.9M | −$60.3M |
| Net income | −$219.9M | −$167.4M | −$153.2M | $111.2M | −$65.6M | −$51.8M |
| Basic EPSper diluted share | — | — | -$3.69 | $2.46 | -$1.52 | -$2.60 |
| Diluted EPSper diluted share | — | — | -$3.69 | $2.38 | -$1.52 | -$2.60 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 5, 2026Form 4 · 10b5-1 | Michaelson JenniferChief Scientific Officer | SellCommon Stock | 200 | $15.58 | $3.1K | 166.8K |
| May 5, 2026Form 4 · 10b5-1 | Michaelson JenniferChief Scientific Officer | SellCommon Stock | 7.8K | $14.60 | $113.9K | 167.0K |
| Mar 5, 2026Form 4 · 10b5-1 | Michaelson JenniferChief Scientific Officer | SellCommon Stock | 8.0K | $15.68 | $125.4K | 170.8K |
| Feb 25, 2026Form 4 · 10b5-1 | Michaelson JenniferChief Scientific Officer | SellCommon Stock | 1.8K | $14.14 | $25.2K | 174.8K |
| Feb 24, 2026Form 4 · 10b5-1 | Michaelson JenniferChief Scientific Officer | SellCommon Stock | 3.6K | $14.47 | $52.1K | 176.6K |